Dobutamine Administration in Cardiogenic Shock

Initial Dosing Protocol

The European Society of Cardiology recommends starting dobutamine at 2.5 μg/kg/min without a loading dose for cardiogenic shock with dominant pulmonary congestion, and titrating gradually at 5-10 minute intervals up to 10 μg/kg/min or until hemodynamic improvement is achieved, with a maximum dose typically ranging from 15-20 μg/kg/min 1, 2, 3
The initial dosing protocol should target hemodynamic goals, including systolic BP >90 mmHg, cardiac index >2.0 L/min/m², and pulmonary capillary wedge pressure <20 mmHg 1, 3

Continuous ECG telemetry is mandatory to monitor for tachyarrhythmias, especially in patients with a baseline heart rate of 120, and invasive arterial blood pressure monitoring is strongly recommended for cardiogenic shock 2, 3, 4
Monitoring should also include signs of improved perfusion, such as warming of extremities, improved mental status, increased urine output, and decreased lactate 3

The American Heart Association recommends considering adding norepinephrine if BP remains <90 mmHg despite dobutamine and adequate fluid resuscitation, as dobutamine alone may cause further hypotension through vasodilation at low doses 2, 3
Dobutamine may worsen tachycardia, increasing the risk of arrhythmias and myocardial oxygen demand, and tolerance develops after 24-48 hours of continuous infusion, requiring planning for mechanical support or alternative strategies if prolonged therapy is needed 2, 3

The European Society of Cardiology recommends starting at 2.5 μg/kg/min and assessing response at 10 minutes, with increments of 2.5 μg/kg/min every 10 minutes up to 10 μg/kg/min, and considering adding norepinephrine rather than pushing dobutamine higher if inadequate response at 10 μg/kg/min 1, 2, 3

The American College of Cardiology recommends avoiding dobutamine as monotherapy if systolic BP <90 mmHg, and using concurrent vasopressor support, as well as avoiding use in patients with severe tachycardia (>100 bpm) without addressing the underlying cause first 2, 3, 4
Gradual weaning of dobutamine is essential to prevent rebound hypotension, with decreases of 2 μg/kg/min steps 2, 3

The European Society of Cardiology recommends considering alternative therapies, such as milrinone, which has a similar efficacy but different adverse event profile, and early consideration for mechanical circulatory support (IABP) if inadequate response to pharmacologic therapy 2, 3, 4